Biotech Finance - The Cassandra Files

Biotech Finance

NOTES: Guardant Health: Blood Money: Guardant's Liquid Biopsy Illusion

Marcus exposes the financial anatomy of Guardant Health's liquid biopsy engine, breaking down the catastrophic cash burn and non-GAAP illusions masking the true unit economics of early cancer screening.

Ginkgo Bioworks

AUDIT: Ginkgo Bioworks: The Empty Pipe: Metagenomics, the BIOSECURE Act, and Ginkgo Bioworks' Retreat from the Sewer Lens

A forensic audit of Ginkgo Bioworks' Q1 2026. Discover how the BIOSECURE Act, cash burn, and biological stochasticity shattered the automated Sewer Lens.

Intellia Therapeutics

AUDIT: Intellia: The Biological API & the Sepsis Pivot

Audit of Intellia Therapeutics' in-vivo CRISPR trials. Examining the MAGNITUDE Phase 3 data, the 'Sepsis Pivot', and the severe clinical solvency risks.